Locations:
Search IconSearch
June 25, 2020/Cancer

The Future of Inguinal Lymph Node Dissection Is Robotic

A closer look at the innovative procedure

650×450-Inguinal-lymph-nodes_robotic-ports_20-URL-1830311

Penile cancer is rare — it accounts for less than 1% of cancers in men in the United States — but its burden is no less insidious. It begins at the penis and advanced cases tend to spread into the inguinal lymph nodes located either superficially or deep within the groin.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

An inguinal lymph node dissection, or lymphadenectomy, has been the standard of care to diagnose, treat and prevent the spread of penile cancer. The procedure has been associated with a high complication rate including flap necrosis and lymphedema. In response, urologists have worked to minimize complications. Greater efforts have been made to improve early detection and develop less invasive surgical techniques.

Jayram Krishnan, DO, MBA, a urologic oncologist in Cleveland Clinic’s Glickman Urological & Kidney Institute, advocates for a robotic approach to inguinal node dissection. “Anecdotally, we see a significant reduction in postoperative complication, paired with a faster recovery, enabling patients to return to their daily activities sooner,” he says.

Procedural details

Adherence is given to all principles of the open surgical approach, but the robot allows surgeons to utilize smaller incisions, sparing the saphenous vein and limiting the area of dissection to superior-medial to the saphenofemoral junction — not performing a sartorious flap. Thus, this technique mitigates many of the risks for wound and edema complications.

“We will follow these modifications during robotic resection of the inguinal nodes. Nodes, both superficial and deep, can be approached in this fashion and both sides can be performed safely during one setting,” he says. He notes that laparoscopic access is obtained with the use of a spacemaker balloon. Once space is created, the robotic ports are placed, as shown below. The robot is placed in a “side dock” configuration on each side.

Advertisement

A closer look of the inguinal lymph node dissection.

Once in the space, the classic “split and roll” technique is used with the robotic instruments. Anatomic landmarks are used to aid in the dissection. Multiple small, medium and large clips can be used through the assistant port for control of lymphatic channels and small vessels.

Alternatively, a robotic vessel sealer can be used. A multi-use laparoscopic bag is used to collect and retrieve lymph node packets as they are liberated from the region. Once the robot is undocked, careful attention is given to wrapping the thighs tightly to prevent postoperative lymphoceles. This can be transitioned to compression stockings in the future. Patients are instructed to ambulate within the first 24 hours.

Improving patient care

Dr. Krishnan has been incorporating this technique into his practice for the last six years, after completing an advanced urological robotic and laparoscopic fellowship training at Cleveland Clinic.

“Ultimately, our goal is to minimize pain and expedite recovery for patients. A robotic approach to inguinal node dissection has really contributed to these improved outcomes,” he says. “The future of this operation will, undoubtedly, be through the use of the robotic platform.”

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad